Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/ refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.

Authors
Category Primary study
Conference2025 ASCO Annual Meeting I
Year 2025
This article has no abstract
Epistemonikos ID: 3a0eb8dcd96ff856e534fec88a7d0fc606ae3e7f
First added on: Sep 03, 2025